Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976277 | 0.85 | GBA1 (0.52) | GBA1GPR119KITCKS1BSKP1 | |
| SCHEMBL30546116 | 0.81 | BACE1 (0.49) | GBA1KITALDH1A1LMNAMAPT | |
| SCHEMBL1964625 | 0.81 | KIT (0.47) | GBA1KITALDH1A1LMNAMAPT | |
| SCHEMBL21274172 | 0.81 | BACE1 (0.49) | GBA1KITALDH1A1LMNAMAPT | |
| SCHEMBL26123863 | 0.79 | KIT (0.46) | GBA1GPR119KITCKS1BSKP1 | |
| SCHEMBL26126469 | 0.79 | KIT (0.46) | GBA1GPR119KITCKS1BSKP1 | |
| SCHEMBL3523914 | 0.79 | BACE1 (0.49) | GBA1KITCKS1BSKP1SKP2 | |
| SCHEMBL30546252 | 0.77 | KIT (0.43) | GBA1GPR119KITCKS1BSKP1 | |
| SCHEMBL26124354 | 0.77 | KIT (0.43) | GBA1GPR119KITCKS1BSKP1 | |
| SCHEMBL26120088 | 0.77 | KIT (0.43) | GBA1GPR119KITCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2337783-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORSOF DOPAMINE D3 RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7825123-B2 | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825123-B2 | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010034656-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORSOF DOPAMINE D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034656-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORSOF DOPAMINE D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100075981-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100075981-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075981-A1 | ISOXAZOLO[4,5]PYRIDIN-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3A | GBA1 3538/4885GPR119 139/4885KIT 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.